[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aortic-dissection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aortic-dissection":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,45,76,106,130,166,193,220,243,265,282,304,321,364,408,431,455,478,503,526,549,570,595,620,639],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100590545","phase-3-study-on-ketorolac-for-improving-outcomes-and-prognosis-in-patients-with-stanford-type-a-aortic-dissection-100590545",false,"NCT06968806","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection","Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection -A Single-Center, Randomized, Double-Blind, Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with Stanford Type A aortic dissection confirmed by imaging and scheduled for emergency surgery.\n\nAged between 18 and 65 years.\n\nSigned informed consent.\n\nExclusion Criteria:\n\n* Patients who are unable to eat independently or require prolonged fasting.\n\nHistory of malignant tumors.\n\nBody weight \\\u003C50 kg.\n\nTraumatic aortic dissection.\n\nPatients with Marfan syndrome.\n\nUnstable vital signs requiring preoperative mechanical support or resuscitation (e.g., IABP \\[Intra-Aortic Balloon Pump\\], ECMO \\[Extracorporeal Membrane Oxygenation\\], LVAD \\[Left Ventricular Assist Device\\])\n\nPatients requiring preoperative endotracheal intubation.\n\nConsciousness impairment, central nervous system dysfunction, or evidence of cerebral malperfusion syndrome upon admission.\n\nPreoperative hematemesis, melena, fresh blood in stool, or symptoms of bowel dilation.\n\nClear evidence of limb malperfusion before surgery.\n\nPresence of organ malperfusion syndrome.\n\nPatients requiring interventional procedures to relieve organ malperfusion before surgery.\n\nHistory of gastrointestinal ulcers or chronic gastrointestinal inflammatory diseases.\n\nHistory of dialysis or renal insufficiency before admission.\n\nHistory of liver disease.\n\nAllergy to ketorolac tromethamine, aspirin, or other nonsteroidal anti-inflammatory drugs (NSAIDs).\n\nChronic inflammatory diseases, autoimmune diseases, or long-term use of steroids or NSAIDs for other reasons.\n\nAbsence of cerebral perfusion during deep hypothermic circulatory arrest.\n\nHistory of major surgery or acute myocardial infarction within 90 days.\n\nHistory of cardiac or major vascular surgery.\n\nPregnant or lactating women.\n\nPatients who refuse to participate in this clinical trial or decline to sign the informed consent form.\n\nAny other conditions deemed unsuitable for participation by the investigator.","ALL","18 Years","65 Years",{"count":21,"type":22},360,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This multicenter, randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of ketorolac in 360 patients with Stanford Type A aortic dissection, conducted between 2025 and 2027. Participants will receive either ketorolac (60 mg intramuscularly \\[IM\\] preoperatively and 30 mg twice daily \\[BID\\] for two days postoperatively) or placebo in addition to standard care. Study outcomes include composite clinical endpoints, postoperative complications, and adverse events, which will be assessed through clinical evaluations, laboratory testing, and imaging studies at predefined intervals up to 90 days. The objective of this trial is to determine whether perioperative administration of ketorolac improves clinical outcomes in this patient population.",[28,29],"Aortic Dissection","Inflammation",[29,28,31],"Ketorolac","RECRUITING","2026-06-19",{"date":35,"type":36},"2026-06-23","ACTUAL",{"date":38,"type":36},"2025-10-27",{"date":40,"type":22},"2028-09-01",{"name":42,"class":43},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100622105","soft-foam-dressings-for-pressure-injury-prevention-of-cardiac-surgery-100622105","NCT07379294","Soft Foam Dressings for Pressure Injury Prevention of Cardiac Surgery","Effectiveness of Using Soft Foam Dressings in Preventing Pressure Injuries During Cardiac Surger","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled to undergo cardiac surgery under general anesthesia\n* Use of cardiopulmonary bypass (CPB) during surgery\n* Expected surgical duration greater than 4 hours\n* Intact skin without pre-existing pressure injury prior to surgery\n\nExclusion Criteria:\n\n* Surgical position other than supine\n* Long-term bedridden status prior to hospital admission\n* Altered consciousness or inability to cooperate\n* History of stroke with residual limb weakness",{"count":53,"type":22},80,[55],"NA","The purpose of this study is to evaluate whether the application of soft foam dressings can reduce the occurrence of surgery-related pressure injuries among patients undergoing cardiac surgery. Specifically, this research aims to investigate differences in pressure injury outcomes before and after the intervention, and to assess the preventive effectiveness of soft foam dressings as an adjunctive skin-protection strategy.",[58,59,60,61,62,63,64,65,28],"CAD - Coronary Artery Disease","CABG","Valve Disease, Heart","Aortic Diseases","Valve Heart Stenosis","Aortic Aneurysm","Mitral Disease","AORTIC VALVE DISEASES","NOT_YET_RECRUITING","2026-05-11",{"date":69,"type":36},"2026-05-14",{"date":71,"type":22},"2026-05-31",{"date":73,"type":22},"2027-05-30",{"name":75,"class":43},"Shih,Wen-Chi",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":44},"100232633","cardiovascular-health-improvement-project-100232633","NCT02306200","Cardiovascular Health Improvement Project","CHIP","Inclusion Criteria:\n\n* Any patient over the age of 18 who is able\u002Fwilling to give informed consent\n* Patients \\\u003C18 years of age with parental consent and assent (if assent is applicable for their age)\n* Diagnosis of:\n* aortic pathology potentially due to a known or suspected inherited condition\n* Idiopathic aortic aneurysm\n* Interesting of novel vascular pathology in the aorta or main branches\n* Family history of aortic or vascular disease\n* Other cardiovascular disease\n* Healthy controls with no apparent cardiovascular disease\n\nExclusion Criteria:\n\n\\- Not willing or able to sign the consent",true,{"count":85,"type":22},15000,"40 Years","OBSERVATIONAL","The goal of this project is to establish a biobank of clinical information, DNA, plasma, and aortic tissue samples from patients with cardiovascular disease as well as healthy controls.",[63,28,90,91,92],"Bicuspid Aortic Valve (BAV)","Heart Failure","Cardiovascular Diseases",[94,95,96,90,28],"Aorta","Abdominal Aortic Aneurysm (AAA)","Thoracic Aortic Aneurysm (TAA)","2026-04-23",{"date":99,"type":36},"2026-04-29",{"date":101,"type":4},"2013-08",{"date":103,"type":22},"2053-08",{"name":105,"class":43},"University of Michigan",{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":23,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100579722","gore-ascending-stent-graft-in-the-treatment-of-de-novo-type-a-aortic-dissections-100579722","NCT06827990","GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections","Evaluation of the GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections","ARISE III","Inclusion Criteria - Primary Arm:\n\nThe subject is\u002Fhas:\n\n1. De novo Type A aortic dissection (≤30 days from symptom onset to index endovascular procedure) compatible with the treatment requirements of the ASG device.\n2. Primarily intended to be treated by placement of the ASG device in the ascending aorta. Distal adjunctive procedures not in contact with the ASG device may be performed during the index endovascular procedure at the discretion of the Investigator.\n3. Anatomic compatibility of the ascending aorta required for implanting the ASG device:\n\n   a) Proximal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm distal to the most distal coronary artery ostium.\n\n   ii. Total aortic diameter between 27mm - 48mm iii. Landing zone cannot be heavily calcified or thrombosed. b) Distal Aortic Landing Zone: i. Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium.\n\n   c) Adequate aortic length\n4. The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria:\n\n   1. ≥80 years of age\n   2. Body mass index (BMI) ≥ 35 kg\u002Fm2\n   3. History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised pulmonary function tests (PFT) on spirometry or other factors as determined by the Investigator)\n   4. Prior Cardiac Surgery\n   5. Hostile Chest (VARC-2 Definition)\n   6. Clinical Frailty Scale 3-7\n   7. Clinical malperfusion (head, gut, lower extremity)\n   8. Transfusion is not possible (e.g., Jehovah's Witness)\n   9. Renal Dialysis prior to aortic dissection\n   10. Chronic renal insufficiency (eGFR\\\u003C60 without dialysis or other documented history of chronic kidney disease prior to dissection)\n5. Age ≥18 years at time of informed consent signature.\n6. Adequate vascular access via transfemoral or retroperitoneal approach.\n7. Informed Consent Form (ICF) signed by the subject or legally authorized representative.\n8. Agrees to comply with protocol requirements, including imaging and 5-year follow-up, as the subject's condition allows.\n\nExclusion Criteria - Primary Arm\n\nThe subject is\u002Fhas:\n\n1. Mechanical heart valve in the aortic position.\n2. Aortic insufficiency grade 3 or greater confirmed during TEE pre-implant.\n3. Indwelling intravascular device that would interfere with or result in contact with planned repair (e.g., contiguous arch graft, LVAD, TAVR device in continuity with aortic tear).\n4. Known degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos Syndrome).\n5. Participation in investigational drug or medical device study within one year of enrollment unless approved by the Sponsor.\n6. Known history of drug abuse within one year of treatment which would affect the ability to obtain follow-up.\n7. Pregnant at time of procedure.\n8. Active infected aorta, mycotic aneurysm.\n9. Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication).\n10. Life expectancy \\\u003C12 months due to presence of another comorbid condition.\n11. Known sensitivities or allergies to the device materials (Previous instance of Heparin Induced Thrombocytopenia type 2 \\[HIT-2\\], known hypersensitivity to heparin, or a history of a hypercoagulability disorder and\u002For state should be considered exclusion if treatment plan includes implant of a TBE device).\n12. Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.\n13. Coronary malperfusion.\n14. Catastrophic neurological complications in the 30 days prior to the dissection diagnosis (e.g., progressively worsening symptoms, coma, Glasgow Coma Scale \\\u003C=8).\n15. Aortic fistula.\n16. In circulatory shock (e.g., systolic blood pressure \\\u003C80 mmHg without inotropes, base deficit \\> -10 mmol\u002FL or -10 mEq\u002FL) at any time prior to the initiation of the index endovascular procedure.\n17. In extreme hemodynamic compromise requiring cardiopulmonary resuscitation at any time prior to the initiation of the index endovascular procedure.\n18. Clinical or radiographic signs of bowel infarction, gastrointestinal hemorrhage, or bowel necrosis (as determined by the implanting physician based on imaging observations, peritoneal signs, surgical exploration, elevated serum lactate levels, low pH, and\u002For acidosis) at any time prior to the initiation of the index endovascular procedure.\n\nInclusion Criteria - Secondary Arm\n\nThe subject is\u002Fhas:\n\n1. De novo Type A aortic dissection (≤90 days from symptom onset until first study procedure) compatible with the treatment requirements of the ASG device alone or the ASG device in combination with the TBE device in the Zone 0 position.\n2. Primarily intended to be treated by placement of the ASG device in the ascending aorta or ASG device in combination with the TBE device in the ascending aorta and aortic arch. Distal adjunctive procedures not in contact with the ASG device may be performed during the index endovascular procedure at the discretion of the Investigator.\n3. Anatomic requirements for intended treatment with the ASG device alone or in combination with the TBE device.\n\n   a) Anatomic compatibility required for implanting the ASG device (Intended treatment with ASG device alone) i. Proximal Aortic Landing Zone:\n   1. Primary entry tear must be in the ascending aorta and ≥ 2 cm distal to the most distal coronary artery ostium.\n   2. Total aortic diameter between 27mm - 48mm.\n   3. Landing zone cannot be heavily calcified or thrombosed. ii. Distal Aortic Landing Zone:\n\n   \u003C!-- -->\n\n   1. Primary entry tear must be in the ascending aorta and ≥ 2 cm proximal to BCA ostium.\n\n      iii. Adequate aortic length\n   2. Anatomic compatibility required for implanting the ASG device (Intended treatment with ASG device and TBE device) i. Proximal Aortic Landing Zone:\n\n   \u003C!-- -->\n\n   1. Primary entry tear must be identified in Zone 0-5.\n   2. Landing zone is native aorta.\n   3. Primary entry tear location is ≥2cm distal to the most distal coronary artery ostium.\n   4. Proximal landing zone must be ≥2cm in the ascending aorta.\n   5. Landing zone cannot be heavily calcified or thrombosed.\n   6. Total aortic landing zone diameter 27mm - 48mm. ii. Branch Vessel Landing Zone:\n\n   \u003C!-- -->\n\n   1. Length of ≥2.5 cm proximal to first major branch vessel.\n   2. Target branch vessel inner diameters of 11-18 mm.\n   3. Target branch vessel landing zone must be in native vessel that cannot be heavily calcified or thrombosed.\n   4. The distal 15mm landing zone cannot be dissected.\n4. The Aortic Treatment Team (as defined by the protocol) attest endovascular repair is in the best interest of the patient AND considers the patient to be high-risk for open surgical repair by meeting at least one of the following criteria:\n\n   1. ≥80 years of age\n   2. BMI ≥ 35 kg\u002Fm2\n   3. History of Respiratory Insufficiency (defined by home O2 usage, exertional dyspnea, imaging evidence of COPD, previous evidence of compromised PFTs on spirometry or other factors as determined by the Investigator)\n   4. Prior Cardiac Surgery\n   5. Hostile Chest (VARC-2 Definition)\n   6. Clinical Frailty Scale 3-9\n   7. Clinical malperfusion (head, gut, lower extremity)\n   8. Transfusion is not possible (e.g., Jehovah's Witness)\n   9. Renal Dialysis prior to aortic dissection\n   10. Chronic renal insufficiency (eGFR\\\u003C60 without dialysis or other documented history of chronic kidney disease prior to dissection)\n5. Age ≥18 years at time of informed consent signature.\n6. Adequate vascular access via transfemoral or retroperitoneal approach.\n7. Informed Consent Form (ICF) signed by the subject or legally authorized representative.\n8. Agrees to comply with protocol requirements, including imaging and 5-year follow-up, as the subject's condition allows.\n\nExclusion Criteria - Secondary Arm:\n\nThe subject is\u002Fhas:\n\n1. Mechanical heart valve in the aortic position.\n2. Pregnant at time of procedure.\n3. Active infected aorta, mycotic aneurysm.\n4. Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication).\n5. Known sensitivities or allergies to the device materials (Previous instance of Heparin Induced Thrombocytopenia type 2 \\[HIT-2\\], known hypersensitivity to heparin, or a history of a hypercoagulability disorder and\u002For state should be considered exclusion if treatment plan includes implant of a TBE device).\n6. Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment.",{"count":115,"type":22},112,[55],"To assess the safety and effectiveness of the ASG device in the treatment of de novo Type A aortic dissections.",[28],"2026-04-13",{"date":121,"type":36},"2026-04-14",{"date":123,"type":36},"2025-09-22",{"date":125,"type":22},"2031-09-01",{"name":127,"class":128},"W.L.Gore & Associates","INDUSTRY",16,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":147,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":44},"100633038","llm-based-intelligent-health-management-assistant-in-life-cycle-health-management-of-cardiac-surgery-patients-100633038","NCT07521488","LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients","Application of Large Language Model-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Patients After Cardiac Surgery: A Prospective Randomized Controlled Study","cFT-LLM","Inclusion Criteria:\n\n1. Aged 18 years or older, any sex\n2. Underwent cardiac surgery at the Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, including but not limited to: coronary artery bypass grafting (CABG), heart valve replacement or repair (aortic valve, mitral valve, or tricuspid valve surgery), great vessel surgery (aortic dissection or aortic aneurysm repair), congenital heart disease correction, or cardiac assist device implantation\n3. Clinically stable after surgery and eligible for hospital discharge\n4. Has access to a smartphone and is capable of independently operating a mobile application, or has a family member available to assist with operation\n5. Voluntarily participates in the study, understands and signs the informed consent form, and is able to comply with the study protocol requirements\n\nExclusion Criteria:\n\n1. Postoperative intensive care unit (ICU) stay exceeding 30 days, or presence of severe uncontrolled postoperative complications such as persistent infection or multi-organ failure\n2. Life expectancy less than 12 months due to advanced malignancy or end-stage organ failure\n3. Severe cognitive impairment, psychiatric disorder, or inability to understand and use a mobile application without available caregiver assistance\n4. Heart transplant recipient\n5. Currently participating in another interventional clinical study\n6. Anticipated inability to complete 12-month follow-up",{"count":139,"type":22},500,[55],"This is a single-center, prospective, randomized, open-label, parallel-controlled clinical study to evaluate the effectiveness of a large language model (LLM)-based intelligent health management assistant in the life-cycle health management of patients after cardiac surgery. A total of 500 adult patients who undergo cardiac surgery (including coronary artery bypass grafting, heart valve surgery, great vessel surgery, congenital heart disease correction, and other cardiac procedures) at Beijing Anzhen Hospital will be randomly assigned in a 1:1 ratio to an intervention group or a control group, stratified by age (\\\u003C65 vs ≥65 years) and surgery type. The intervention group will use the LLM-based mobile health management application in addition to standard postoperative care, while the control group will receive standard postoperative care alone. The application integrates multimodal clinical data into a personalized health profile and provides surgery-type-specific postoperative management recommendations, medication adherence reminders, complication early warning, and cardiac rehabilitation guidance. The primary outcome is the composite endpoint of major adverse cardiac and cerebrovascular events (MACCE), defined as all-cause death, non-fatal myocardial infarction, non-fatal stroke, or unplanned cardiovascular reoperation\u002Freintervention, within 12 months after randomization. Secondary outcomes include health-related quality of life (EQ-5D-5L), cardiovascular rehospitalization rate, medication adherence (MMAS-8), postoperative complication rate, and cardiac rehabilitation achievement rate. Follow-up visits are scheduled at 1, 3, 6, 9, and 12 months post-randomization.",[143,144,63,28,145,146],"Coronary Artery Bypass Grafting","Heart Valve Disease","Congenital Heart Disease","Cardiac Surgical Procedures",[148,149,150,151,152,153,154,155,156,157],"Large Language Model","Artificial Intelligence","Cardiac Surgery","Postoperative Health Management","Digital Health","Medication Adherence","Cardiac Rehabilitation","MACCE","Mobile Health Application","Personalized Health Management","2026-04-08",{"date":119,"type":36},{"date":161,"type":22},"2026-05-01",{"date":163,"type":22},"2027-12-31",{"name":165,"class":43},"Beijing Anzhen Hospital",{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":7},"100420397","valved-graft-pmcf-study-100420397","NCT04754217","Valved Graft PMCF Study","Valved Graft Post-Market Clinical Follow-up Study","Inclusion Criteria:\n\n* cardiac surgery including the implant of a VAVGJ or CAVGJ for native or prosthetic valve replacement\n\nExclusion Criteria:\n\n* anticoagulation therapy intolerant\n* active endocarditis\n* anatomical or medical, surgical, psychological or social contraindications",{"count":174,"type":22},260,"Multicenter, global, prospective, non-randomized, interventional, post-market trial. All subjects enrolled will receive an Abbott Valved Graft device.",[177,178,28],"Aortic Valve Disease","Ascending Aorta Abnormality",[180,181,182,183,184],"Aortic Root Replacement","Ascending Aorta Replacement","Valved Graft","CAVGJ","VAVGJ","2026-04-07",{"date":119,"type":36},{"date":188,"type":36},"2021-07-13",{"date":190,"type":22},"2029-09",{"name":192,"class":128},"Abbott Medical Devices",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":17,"minAge":200,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":44},"100419818","safety-and-efficacy-of-endovascular-repair-of-complex-aortic-pathology-with-physician-modified-endovascular-grafts-pmegs-100419818","NCT04746677","Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)","Single-Center Investigational Device Exemption Trial: Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)","INCLUSION CRITERIA:\n\nGeneral inclusion criteria (applicable to all 3 study arms):\n\n* Aortic pathology that fits one of the study arms (see below for detailed description)\n* Aortic pathology that cannot be treated within the Instructions for Use of an FDA- approved, commercially-available device\n* Aortic aneurysm that can be treated within the Instructions for Use of an FDA-approved, commercially-available custom-manufactured device but deemed unsafe to wait the required time for device manufacturing\n* Subject is at high-risk of morbidity and mortality with open surgical repair based on cardiopulmonary function, extent of comorbid disease, and anatomic complexity\n* Iliac and\u002For femoral access vessel morphology that is compatible with vascular access techniques, devices, or accessories, with or without use of a surgical or endovascular conduit\n* Non-aneurysmal aortic segment proximal to the aortic pathology with a:\n\n  * Minimum neck length of 20 mm\n  * Diameter between 20 - 42 mm\n* Non-aneurysmal aortic or iliac segment distal to the aortic pathology with:\n\n  * Aortic distal fixation site greater than 20 mm in length and diameter between 20-42 mm\n  * Iliac artery distal fixation site greater than 10 mm in length and diameter range 8- 25 mm\n* Age ≥21 years old\n* Life expectancy: ≥2 years\n\nArm1:\n\n* Complex abdominal aortic aneurysm, specifically juxtarenal or suprarenal abdominal aortic aneurysm or type IV thoracoabdominal aortic aneurysm, with maximum diameter of ≥5.5 cm for men or ≥5.0 cm for women, growth ≥0.5 cm in 6 months, or concomitant iliac aneurysm ≥3 cm\n* Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and\u002For CA for repair, without aneurysmal disease extending above the diaphragmatic hiatus\n* Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and\u002For CA for repair, without aneurysmal disease above the diaphragmatic hiatus\n* Saccular complex abdominal aortic aneurysm deemed at significant risk for rupture\n* Symptomatic complex aortic aneurysm\n* Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and\u002For CA, without involvement of the aorta above the diaphragmatic hiatus\n* Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and\u002For CA, without involvement of the aorta above the diaphragmatic hiatus\n\nArm2:\n\n* Type I, II, or III thoracoabdominal aortic aneurysm with maximum diameter of ≥5.5 cm, or growth ≥0.5 cm in 6 months\n* Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and\u002For CA for repair with aneurysmal disease extending above the diaphragmatic hiatus\n* Prior thoracic endovascular aneurysm repair with loss of distal seal requiring incorporation of the renal arteries, SMA, and\u002For CA for repair\n* Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and\u002For CA for repair, with aneurysmal disease above the diaphragmatic hiatus\n* Saccular type I, II, or III thoracoabdominal aortic aneurysm deemed at significant risk for rupture\n* Symptomatic type I, II, or III thoracoabdominal aortic aneurysm\n* Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and\u002For CA, with involvement of the aorta above the diaphragmatic hiatus\n* Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and\u002For CA, with involvement of the aorta above the diaphragmatic hiatus\n\nArm 3:\n\n* Acute or chronic type B aortic dissection with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or persistence of symptoms despite optimal medical therapy\n* Prior repair of type A dissection and development of acute or chronic type B dissection component with indication for repair (listed above)\n* Aortic intramural hematoma (IMH) with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or more typically, persistence of symptoms despite optimal medical therapy\n\nArm 4\n\n* Patient does not meet the inclusion\u002Fexclusion criteria of Arms 1 - 3\n* Patient has prohibitive operative risk for open repair and no other viable endovascular treatment option\n* Estimated perioperative risk is lower than the estimated 1-year mortality without surgery\n\nEXCLUSION CRITERIA:\n\nGeneral Exclusion Criteria\n\n* Subject is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site\n* Subject is unwilling to comply with the follow-up schedule\n* Inability or refusal to give informed consent by subject or legal representative\n* Subject is pregnant or breastfeeding\n* Subject has a ruptured aneurysm\n\nArm 5 • Patient meets criteria for Arms 1-4\n\n\\- Patient is undergoing repair using the TREO bifurcated stent graft\n\nIndications for using TREO bifurcated stent graft:\n\n* Patient has undergone a prior endovascular aortic repair and meets criteria for repair; OR\n* -Patient has measured length from the lowest renal artery to the aortic bifurcation (either de novo or from a prior endograft) \\\u003C 115 mm; OR\n\n  * In patients with notable vessel tortuosity, where centerline measurement may not accurately reflect the distance covered needed in situ; OR\n  * Additional clinical or anatomic scenarios where forthcoming experience may demonstrate the TREO endograft to be superior to the currently-used Alpha\u002FAlpha 2 endograft.\n\nMedical Exclusion Criteria\n\n* Known sensitivities or allergies to the materials of construction of the devices\n* Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed\n* Uncorrectable coagulopathy\n* Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment\n* Systemic or local infection that may increase the risk of endovascular graft infection\n* Diagnosis of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome)\n\nAnatomic Exclusion Criteria\n\n* Inability to perform open or endovascular iliac conduit in patients with inadequate femoral\u002Filiac access\n* Excessive thrombus or calcification within the neck of the aneurysm\n* Visceral vessel anatomy not compatible with placement of a physician-modified endovascular graft due to occlusive disease or small size","21 Years",{"count":202,"type":22},220,[55],"The primary objective of this study is to examine the safety and effectiveness of physician-modified endovascular grafts (PMEGs) for endovascular repair of complex aortic pathology in high-risk patients. The study is divided into three study arms based on the subject's aortic pathology: (1) Complex abdominal aortic aneurysm (AAA); (2) Thoracoabdominal aortic aneurysm; and (3) Aortic dissection.",[206,207,28],"Abdominal Aortic Aneurysm","Thoracoabdominal Aortic Aneurysm",[209,210,211],"Fenestrated endovascular aortic repair","Branched endovascular aortic repair","Complex aortic aneurysm repair","2026-04-02",{"date":158,"type":36},{"date":215,"type":36},"2021-03-15",{"date":217,"type":22},"2031-03-31",{"name":219,"class":43},"Beth Israel Deaconess Medical Center",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100631022","nutritional-ketosis-marfan-100631022","NCT07495267","Nutritional Ketosis Marfan","Nutritional Ketosis as a Novel Therapeutic Strategy to Stabilize Chronic Aortic Dissection in Marfan Syndrome","Inclusion Criteria:\n\n1. Adults between 18 and 50 years old.\n2. Ability to understand and willingness to sign an Institutional Review Board (IRB) approved written informed consent document.\n3. Genetically or clinically confirmed Marfan syndrome\n4. Chronic descending thoracic aortic dissection present for at least three months\n5. Maximal descending thoracic aortic diameter must measure between 4.0 and 5.0 cm at baseline on contrast-enhanced computed tomography angiography (CTA)\n6. Have been clinically stable and consistent antihypertensive regimen for at least four weeks\n\nExclusion Criteria:\n\n1. Acute or rapidly enlarging dissection (\\>0.5 cm increase over the preceding three months)\n2. Prior descending thoracic aortic repair or endograft placement\n3. Advanced renal or hepatic dysfunction\n4. Poorly controlled diabetes requiring insulin\n5. Active malignancy, pregnancy, or other metabolic or nutritional disorders that would contraindicate ketogenic therapy\n6. Body mass index below 18 kg\u002Fm²\n7. Inability to comply with dietary restrictions or follow-up imaging\n8. Current enrollment in another interventional study, which in the opinion of the principal investigator, may confound study results.\n9. Patients who, in the opinion of the principal investigator, are not suitable candidates for study participation.","50 Years",{"count":229,"type":22},15,[55],"In this pilot clinical trial, the investigators will test whether a carefully supervised ketogenic diet can safely help people with Marfan syndrome who already have a chronic or residual aortic dissection. Fifteen participants will work with a study coordinator and dietitian to learn how to follow the diet and will have regular guidance and check-ins. The participants will measure their blood ketone levels at home with a simple finger-stick device and relay their readings to the research team. Every three months, blood samples will also be collected to confirm the body's level of ketosis.\n\nParticipants will continue their usual heart and blood-pressure medicines and regular visits with their doctors. Standard of care computed tomography (CT) scans of the aorta will be performed at the start of the study and then again at 6 and 12 months to see if the aorta changes in size.\n\nThe main goal is to see how many patients can avoid needing aortic surgery within one year, compared with what is normally expected from past studies. The investigators will also track how well patients follow the diet, how their aorta changes, and whether inflammation in their blood decreases.",[233,28],"Marfan Syndrome","2026-03-22",{"date":236,"type":36},"2026-03-27",{"date":238,"type":22},"2026-03-13",{"date":240,"type":22},"2028-03-01",{"name":242,"class":43},"Washington University School of Medicine",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":23,"phases":252,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":264},"100558428","false-lumen-treatment-for-prevention-of-aortic-growth-using-shape-memory-polymer---first-in-human-study-100558428","NCT06550986","False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study","FLAGSHIP_NZL","Inclusion Criteria:\n\n* ≥18 years of age.\n* A candidate for false lumen (FL) embolization with a type B dissection, and no prior primary entry tear\u002FTL treatment, OR\n* A candidate for FL embolization with a type B or type A dissection, in whom the primary entry tear\u002FTL was treated in a previous procedure, and is now presenting with a FL requiring treatment.\n\nExclusion Criteria:\n\n* An inability to provide informed consent.\n* Enrolled in another clinical study other than a registry.\n* Hyperacute or acute aortic dissection (\\\u003C15 days from symptom onset).\n* Untreated or uncovered primary entry\u002Freentry tear proximal to left subclavian artery (before FL treatment with the investigational product).\n* Vascular disease, aortic rupture, and\u002For anatomy and\u002For dissection membrane condition that precludes the safe access and positioning of an introducer sheath and delivery (and expansion) of the investigational product into the FL.\n* Prior treatment of the FL.\n* Planned use of investigational devices to treat the primary entry tear and\u002For TL.\n* Absence of\u002Finability to create a reentry tear\u002Ffenestration adequately positioned and large enough to allow introducer sheath access into the FL.\n* Planned use of FL embolic devices other than the investigational product.\n* Prior abdominal aortic aneurysm (AAA) treatment.\n* Planned concomitant major surgery (e.g., gastrointestinal surgery).\n* Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos syndrome).\n* Coagulopathy or uncontrolled bleeding disorder.\n* Serum creatinine level \\>220 µmol\u002FL (within 90 days prior to the procedure).\n* Cerebrovascular accident within 90 days prior to the procedure.\n* Myocardial infarction and\u002For major heart surgery within 90 days prior to the procedure.\n* Atrial fibrillation that is not well rate controlled.\n* Unable or unwilling to comply with study follow-up requirements.\n* Life expectancy of \\\u003C2 years postprocedure.\n* Known hypersensitivity or contraindication to platinum, iridium, or polyurethane.\n* A condition that inhibits radiographic visualization during the study procedure and planned follow-up imaging.\n* History of allergy to contrast medium that cannot be managed medically.\n* Uncontrolled comorbid medical condition, including mental health issues, that, in the opinion of the investigator, would adversely affect participation in the study.\n* Participant is planning to become pregnant or is currently pregnant or lactating. For participants of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the study.",{"count":251,"type":22},30,[55],"To determine the safety and feasibility of the investigational product to reduce aortic dissection false lumen perfusion.",[28],"2026-03-19",{"date":257,"type":36},"2026-03-23",{"date":259,"type":36},"2026-02-24",{"date":261,"type":22},"2029-02-15",{"name":263,"class":128},"Shape Memory Medical, Inc.",2,{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":247,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":253,"conditions":274,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":4},"100622717","false-lumen-treatment-for-prevention-of-aortic-growth-using-shape-memory-polymer---first-in-human-study-flagshipchl-100622717","NCT07387250","False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study (FLAGSHIP_CHL)","FLAGSHIP_CHL","Inclusion Criteria:\n\n* ≥18 years of age.\n* A candidate for false lumen (FL) embolization with a type B dissection, and no prior primary entry tear\u002FTL treatment, OR\n* A candidate for FL embolization with a type B or type A dissection, in whom the primary entry tear\u002FTL was treated in a previous procedure, and is now presenting with a FL requiring treatment.\n\nExclusion Criteria:\n\n* An inability to provide informed consent.\n* Enrolled in another clinical study other than a registry.\n* Hyperacute or acute aortic dissection (\\\u003C15 days from symptom onset).\n* Untreated or uncovered primary entry\u002Freentry tear proximal to left subclavian artery (before FL treatment with the investigational product).\n* Vascular disease, aortic rupture, and\u002For anatomy and\u002For dissection membrane condition that precludes the safe access and positioning of an introducer sheath and delivery (and expansion) of the investigational product into the FL.\n* Prior treatment of the FL.\n* Planned use of investigational devices to treat the primary entry tear and\u002For TL.\n* Absence of\u002Finability to create a reentry tear\u002Ffenestration adequately positioned and large enough to allow introducer sheath access into the FL.\n* Planned use of FL embolic devices other than the investigational product.\n* Prior abdominal aortic aneurysm (AAA) treatment.\n* Planned concomitant major surgery (e.g., gastrointestinal surgery).\n* Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos syndrome).\n* Coagulopathy or uncontrolled bleeding disorder.\n* Serum creatinine level \\>2.5 mg\u002FdL (within 90 days prior to the procedure).\n* Cerebrovascular accident within 90 days prior to the procedure.\n* Myocardial infarction and\u002For major heart surgery within 90 days prior to the procedure.\n* Atrial fibrillation that is not well rate controlled.\n* Unable or unwilling to comply with study follow-up requirements.\n* Life expectancy of \\\u003C2 years postprocedure.\n* Known hypersensitivity or contraindication to platinum, iridium, or polyurethane.\n* A condition that inhibits radiographic visualization during the study procedure and planned follow-up imaging.\n* History of allergy to contrast medium that cannot be managed medically.\n* Uncontrolled comorbid medical condition, including mental health issues, that, in the opinion of the investigator, would adversely affect participation in the study.\n* Participant is planning to become pregnant or is currently pregnant or lactating. For participants of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the study.",{"count":229,"type":22},[55],[28],"2026-03-17",{"date":255,"type":36},{"date":278,"type":22},"2026-04-01",{"date":280,"type":22},"2029-04-01",{"name":263,"class":128},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":83,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":289,"targetDuration":291,"studyType":87,"phases":4,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":303},"100362959","montalcino-aortic-consortium-precision-medicine-for-heritable-thoracic-aortic-disease-100362959","NCT04005976","Montalcino Aortic Consortium: Precision Medicine for Heritable Thoracic Aortic Disease","MAC:H-TAD","Inclusion Criteria:\n\n* Patients and their relatives with a confirmed pathogenic, likely pathogenic variant, or variant of unknown clinical significance in at least one of the H-TAD genes (i.e. TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, ACTA2, MYH11, MYLK, PRKG1, MAT2A, MFAP5, LOX, COL3A1, FOXE3, and FBN1).\n* Patients of all ages, sex and race for which informed consent can be obtained.\n\nExclusion Criteria:\n\n* Patients without a confirmed causative variant for H-TAD.",{"count":290,"type":22},5000,"20 Years","The Montalcino Aortic Consortium (MAC) will provide the infrastructure to assemble large cohorts of patients with mutations in known heritable thoracic aortic disease (H-TAD) genes, define the phenotype associated with these genes, and determine genetic and environmental modifiers of H-TAD.",[63,28,61],"2026-01-29",{"date":296,"type":36},"2026-02-02",{"date":298,"type":36},"2016-06-15",{"date":300,"type":22},"2037-01-01",{"name":302,"class":43},"The University of Texas Health Science Center, Houston",20,{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":247,"acronym":309,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":4},"100573011","false-lumen-treatment-for-prevention-of-aortic-growth-using-shape-memory-polymer---first-in-human-study-flagshipfra-100573011","NCT06740721","False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study (FLAGSHIP_FRA)","FLAGSHIP_FRA",{"count":229,"type":22},[55],"To determine the safety and feasibility of investigational product to reduce aortic dissection false lumen perfusion.",[28],"2026-01-27",{"date":294,"type":36},{"date":317,"type":22},"2026-10-01",{"date":319,"type":22},"2029-01-03",{"name":263,"class":128},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":330,"conditions":331,"keywords":345,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":44},"100434493","developing-a-decision-instrument-to-guide-abdominal-pelvic-ct-imaging-of-blunt-trauma-patients-100434493","NCT04937868","Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients","NEXUS AP CT","Inclusion Criteria:\n\nBlunt trauma patients who undergo abdominal-pelvic CT imaging during their initial trauma evaluation in the emergency department.\n\nExclusion Criteria:\n\nNone",{"count":329,"type":22},12000,"Unrecognized abdominal and pelvic injuries can result in catastrophic disability and death. Sporadic reports of \"occult\" injuries have generated concern, and physicians, fearing that they may miss such an injury, have adopted the practice of obtaining computed tomography on virtually all patients with significant blunt trauma. This practice exposes large numbers patients to dangerous radiation at considerable expense, while detecting injuries in a small minority of cases.\n\nExisting data suggest that a limited number of criteria can reliably identify blunt injury victims who have \"no risk\" of abdominal or pelvic injuries, and hence no need for computed tomography (CT), without misidentifying any injured patient. It is estimated that nationwide implementation of such criteria could result in an annual reduction in radiographic charges of $75 million, and a significant decrease in radiation exposure and radiation induced malignancies.\n\nThis study seeks to determine whether \"low risk\" criteria can reliably identify patients who have sustained significant abdominal or pelvic injuries and safely decrease CT imaging of blunt trauma patients. This goal will be accomplished in the following manner:\n\nAll blunt trauma victims undergoing computed tomography of the abdomen\u002Fpelvis in the emergency department will undergo routine clinical evaluations prior to radiographic imaging. Based on these examinations, the presence or absence of specific clinical findings (i.e. abdominal\u002Fpelvic\u002Fflank pain, abdominal\u002Fpelvic\u002Fflank tenderness, bruising abrasions, distention, hip pain, hematuria, hypotension, tachycardia, low or falling hematocrit, intoxication, altered sensorium, distracting injury, positive FAST imaging, dangerous mechanism, abnormal x-ray imaging) will be recorded for each patient, as will the presence or absence of abdominal or pelvic injuries. The clinical findings will serve as potential imaging criteria. At the completion of the derivation portion of the study the criteria will be examined to find a subset that predicts injury with high sensitivity, while simultaneously excluding injury, and hence the need for imaging, in the remaining patients. These criteria will then be confirmed in a separate validation phase of the study.\n\nThe criteria will be considered to be reliable if the lower statistical confidence limit for the measured sensitivity exceeds 98.0%. Potential reductions in CT imaging will be estimated by determining the proportion of \"low-risk\" patients that do not have significant abdominal or pelvic injuries.",[332,333,334,335,336,337,338,339,340,341,28,342,343,344],"Abdominal Injury","Pelvic Fracture","Genital Hemorrhage","Lumbar Spine Injury","Hip Injuries","Liver Injury","Spleen Injury","Renal Injury","Diaphragm Injury","Aortic Rupture","Bowel Disease","Vascular System Injuries","Sacral Fracture",[346,347,348,349,350,351,352,353,354],"Blunt trauma","Abdominal injury","Pelvic injury","Spine injury","Genital injury","Vascular injury","Hip injury","Computed tomography","Decision instrument","2026-01-09",{"date":357,"type":36},"2026-01-13",{"date":359,"type":36},"2018-01-15",{"date":361,"type":22},"2027-06-15",{"name":363,"class":43},"University of California, Los Angeles",{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":380,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":44},"100212530","evaluation-of-the-cook-custom-aortic-endograft-the-zenith-t-branch-endovascular-graft-and-surgeon-modified-endograft-in-treating-aortic-pathologies-100212530","NCT02043691","Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies","Evaluation of All-Cause Mortality and Pulmonary Morbidity in Treating Juxtarenal, Suprarenal, Thoracoabdominal, and Aortic Arch Pathologies Using Cook Custom Aortic Endografts, the Zenith t-Branch Endovascular Graft, and the Surgeon-Modified Endograft","Inclusion Criteria:\n\n* Juxtarenal, suprarenal, and thoracoabdominal aortic pathology as follows in hemodynamically stable patients:\n\n  1. Intact or contained ruptured aortic or aortoiliac aneurysms (atherosclerotic\u002Fdegenerative or saccular) involving or in close approximation to the visceral segment of the aorta.\n\n     1. Diameter \\> 5.5 cm if asymptomatic, or 5.0 cm with enlargement of \\> 0.5 cm in 6 months.\n     2. History of growth \\> 0.5 cm per year\n     3. Any size if ruptured or symptomatic\n  2. Penetrating aortic ulcer (PAU)\n\n     1. \\> 2.0 cm in depth\n     2. Any size if contained ruptured or symptomatic\n  3. Subacute (\\>14 days) or chronic (\\>20 days) aortic dissection with aneurysmal degeneration with at least one of the following:\n\n     1. Total aortic diameter \\> 5.5 cm if asymptomatic\n     2. Total aortic diameter \\> 4.5 cm if symptomatic\n     3. Total aortic diameter \\> 5.0 cm and history of growth \\> 0.5 cm in 6 months\n* Aortic Arch pathology:\n\n  1. Aneurysm, Ascending thoracic aortic pseudoaneurysm, Type A thoracic aortic dissection, Retrograde type A thoracic aortic dissection between the Sinus of Valsalva and the innominate artery orifice (without involvement of the Aortic Valve), or Ascending penetrating aortic ulcer with and without intramural hematoma\n  2. Suitable iliac artery and brachial artery access\n  3. Absence of severe landing zone (\\> 90 degree) angulation that would preclude necessary device delivery\u002Fseal\u002Ffixation.\n  4. Suitable iliac artery access to accommodate device delivery system.\n  5. Target arteries for arch branches:\n\n     1. \\\u003C 24 mm diameter\n     2. Adequate landing zone length to obtain proximal and distal seal.\n     3. Free from dissection precluding adequate seal in distal landing zone of branch stent and severe tortuosity\u002Fthrombus\u002Fcalcification.\n* Aortic Arch Aneurysm\n\n  1. Proximal aortic fixation zone:\n\n     1. Native aorta or surgical graft\n     2. Diameter: 20 - 42 mm\n  2. Proximal neck length \\> 20 mm\n  3. Must occur distal to coronary arteries and any coronary artery bypass grafts that are considered patent and necessary for proper cardiac perfusion.\n  4. Distal aortic fixation zone:\n\n     1. Native aorta or surgical graft\n     2. Diameter: 20 - 44 mm\n  5. Distal neck length \\> 20 mm. However, if dissection, distal graft may land in dissected aorta.\n  6. Supra-aortic trunk (brachiocephalic) vessels (Any combination of arteries may be used for repair) A. Innominate artery\n\n     1. Native vessel or surgical graft\n     2. Diameter: 8 - 22 mm\n     3. Length of sealing zone \\> 10 mm\n     4. Acceptable tortuosity B. Left (or right) common carotid artery\n\n     \u003C!-- -->\n\n     1. Native vessel or surgical graft\n     2. Diameter 5 - 20 mm\n     3. Length of sealing zone \\> 10 mm C. Left (or right) subclavian artery\n\n     \u003C!-- -->\n\n     1. Native vessel or surgical graft\n     2. Diameter 5 - 20 mm\n     3. Length of sealing zone \\> 10 mm\n* Aortic Dissection\n\n  1. Access into the true lumen from the groin and at least one supra-aortic trunk vessel.\n  2. Seal zone in the target aorta (or surgical graft) that is proximal to the primary dissection, such that a stent-graft would be anticipated to seal off the dissection lumen.\n  3. Seal zone in the target supra-aortic trunk vessels that is distal to the dissection, anticipated to seal off the dissection lumen or surgically created.\n  4. True lumen size large enough to deploy the device and still gain access into the target branch.\n\nGeneral Exclusion Criteria:\n\n* Less than 18 years of age\n* Life expectancy less than 12 months based on the surgeon's assessment\n* Pregnant or breastfeeding or planning on becoming pregnant within 60 months\n* Inability or refusal to give informed consent\n* Unwilling or unable to comply with the follow-up schedule\n* Less than 30 days beyond primary endpoint for other investigative drug or device study\n\nMedical Exclusion Criteria:\n\n* Known allergy to the device components (i.e. stainless steel, polyester, solder, gold, or nitinol)\n* History of anaphylactic reaction to contrast material that cannot be adequately premedicated\n* Systemic or local infection that may increase the risk of endovascular graft infection.\n* Baseline eGFR \\\u003C 30 mL\u002Fmin (calculated by the Modification of Diet in Renal Disease formula) and not on hemo- or peritoneal dialysis. If the patient is currently on dialysis, or is currently planning on initiating dialysis, then they may undergo repair.\n* Body habitus that would inhibit X-ray visualization of the aorta.\n* Major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair.\n* Unstable angina, defined as a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina.\n* Irreversible coagulopathy\n\nAnatomical Exclusion Criteria:\n\n* Aortic transection due to acute trauma.\n* Infectious (\"mycotic\") etiology of the aortic disease.\n* Significant occlusive disease or tortuosity precluding delivery of the device components.\n* Juxtarenal, Suprarenal, and Thoracoabdominal:\n* Proximal Landing zone \\\u003C 20 mm in length. The proximal landing zone can be within zones 2 through 8, with least 20 mm of proximal seal and fixation in aorta or Dacron.\n* Proximal neck, defined as the thoracic aorta distal to the native left carotid artery, measured outer wall to outer wall on a sectional image (CT) \\> 41 mm in diameter or \\\u003C 18 mm in diameter\n* Distal landing zone \\\u003C 20 mm in length if the landing zone is in the aorta, or \\\u003C 20 mm if the landing zone is in the iliac arteries or in Dacron (in the event the patient has had a previous or concomitant aortic or aorto-iliac reconstruction).\n* Untreatable branch vessel stenosis.\n* Anatomy that would not allow maintenance of at least one patent hypogastric artery.\n* Signs that the inferior mesenteric artery (IMA) is indispensable (i.e. angiographic visualization or a large IMA, filling of superior mesenteric artery (SMA) via collaterals, stenosis of celiac or SMA or oblique views) and the indispensable IMA is not amenable to treatment with a graft branch or fenestration.\n* Branching, duplication, aneurysm or untreatable stenosis of the celiac, SMA or renal arteries that would preclude implantation of the investigational devices.\n* Aortic arch:\n* Proximal neck \\> 44 mm or \\\u003C 28 mm in diameter\n* Inadequate landing zone to allow adequate distal seal of exclusion of false lumen perfusion in dissection.\n* Untreatable branch vessel stenosis.\n* Significant occlusive disease, tortuosity, or calcification that would prevent endovascular access.\n* Patients qualifying for an industry-sponsored study allowing for a similar repair will be enrolled in the industry-sponsored study.",{"count":372,"type":22},410,[55],"This is a single-center study to evaluate the safety and effectiveness of three investigational devices, the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and the Surgeon-Modified Endografts in the treatment of Juxtarenal, Suprarenal, Thoracoabdominal, and Aortic Arch pathologies involving the at least one brachiocephalic artery or visceral vessels.\n\nThe three investigational devices offer an endovascular approach to treat complex aortic pathologies that cannot be treated with commercially available devices. This customized, endovascular approach has the potential to decrease hospital length of stay, pulmonary complications, and in-hospital mortality.",[376,377,207,378,379,28],"Juxtarenal Aortic Aneurysm","Suprarenal Aortic Aneurysm","Penetrating Aortic Ulcer","Aortic Arch Aneurysm",[381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398],"Endovascular","Aortic","Aneurysm","Thoracoabdominal","Juxtarenal","Suprarenal","Endograft","Fenestrated","Branched","Complex","Abdominal","Thoracic","Stent","Stentgraft","Arch","Ascending","Dissection","Descending","2026-01-02",{"date":401,"type":36},"2026-01-06",{"date":403,"type":36},"2014-06",{"date":405,"type":22},"2027-10",{"name":407,"class":43},"University of Alabama at Birmingham",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":44},"100614792","clear-trial-ca330-cytokine-adsorption-column-for-anticoagulantantiplatelet-patients-in-non-elective-cpb-surgery-100614792","NCT07284199","CLEAR Trial: CA330 Cytokine Adsorption Column for Anticoagulant\u002FAntiplatelet Patients in Non-Elective CPB Surgery.","A Multicenter Randomized Controlled Trial of the CA330 Haemoadsorption Device in Patients for Limiting Excess Anticoagulation in Non-elective caRdiac Surgery With Cardiopulmonary Bypass","CLEAR","Inclusion Criteria:\n\n* Patients scheduled to undergo non-elective cardiovascular surgery requiring cardiopulmonary bypass;\n* Patients currently receiving one or more of the following medications - indobufen, ticagrelor, warfarin, cilostazol, dabigatran, rivaroxaban, or apixaban - with the last dose administered within the drug washout period.\n\nExclusion Criteria:\n\n* Patients with a history of chronic liver failure, stage 5 chronic kidney disease (CKD5), or requiring regular dialysis;\n* Patients in special physiological states: pregnancy or puerperium;\n* Patients with advanced-stage malignancy or scheduled cardiovascular surgery related to tumor management;\n* Patients with allergic reactions to cytokine adsorption column resin or related components;\n* Patients with known bleeding risk due to hematologic disorders such as heparin-induced thrombocytopenia, hemophilia, or acute sickle cell crisis;\n* Patients with severe infection, including severe sepsis.","80 Years",{"count":418,"type":22},120,[55],"The goal of this clinical trial is to evaluate whether the CA330 cytokine adsorption column can reduce perioperative severe bleeding adverse events in patients receiving anticoagulant and\u002For antiplatelet therapy who undergo non-elective cardiac surgery with cardiopulmonary bypass.\n\nThe main questions it aims to answer are:\n\n* Does the use of the CA330 cytokine adsorption column lower the incidence of perioperative severe bleeding compared with standard care?\n* Does the intervention improve short-term clinical outcomes, such as transfusion requirements, reoperation rates for bleeding, or overall postoperative recovery?\n\nIf there is a comparison group: Researchers will compare patients treated with the CA330 cytokine adsorption column versus patients receiving standard cardiopulmonary bypass management to see if cytokine adsorption provides additional safety and efficacy benefits.\n\nParticipants will:\n\n* Undergo non-elective cardiac surgery requiring cardiopulmonary bypass.\n* Be randomly assigned to receive either the CA330 cytokine adsorption column integrated into the CPB circuit (intervention arm) or standard CPB management without the device (control arm).\n* Be monitored for perioperative bleeding outcomes, transfusion needs, reoperation rates, and overall postoperative prognosis.",[59,28,422],"Valvular Heart Diseases","2025-12-14",{"date":425,"type":36},"2025-12-16",{"date":427,"type":22},"2025-12-15",{"date":429,"type":22},"2028-06-30",{"name":165,"class":43},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":454},"100398727","nexus-aortic-arch-clinical-study-to-evaluate-safety-and-effectiveness-100398727","NCT04471909","NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness","A Multi-arm, Multi-Center, Non-Randomized, Prospective, Clinical Study to Evaluate the Safety and Effectiveness of the NEXUS Aortic Arch Stent Graft System in Treating Thoracic Aortic Lesions Involving the Aortic Arch","TRIOMPHE","Inclusion Criteria:\n\n1. Male and female age ≥ 18.\n2. Proximal\u002Fascending native or previously implanted surgical graft landing zone of appropriate length\n3. Proximal\u002Fascending native or previously implanted surgical graft landing zone of appropriate diameter\n4. Distal\u002Fdescending native landing zone of appropriate length\n5. Distal\u002Fdescending native landing zone of appropriate diameter\n6. Brachiocephalic trunk native landing zone of appropriate length\n7. Brachiocephalic trunk native landing zone of appropriate diameter\n8. Appropriate take off angle between the Brachiocephalic Artery and the Aortic Arch perpendicular\n9. Appropriate aortic arch perpendicular diameter\n10. Chronic dissection with at least one of the following conditions:\n\n    1. An aortic aneurysm with a maximum diameter ≥ 55 mm\n    2. Rapidly expanding false lumen (growth of \\> 0.5 cm\u002F6 months)\n    3. Compressed true lumen associated with end organ malperfusion\n    4. Symptomatic\n11. Aneurysm with at least one of the following conditions:\n\n    1. Dilatation of the aortic arch larger than 5 cm in diameter for subject with fusiform aneurysm\n    2. Dilatation of the aortic arch is 1.5 times the normal diameter for subjects ascending or descending\n    3. Dilation of the aortic arch larger than 2.5 cm for subject with saccular aneurysm\n    4. Symptomatic aneurysm of the aortic arch\n    5. Aortic diameter growth rate \\> 5mm per 6 months\n    6. Postoperative pseudoaneurysm expanding from anastomotic suture lines\n12. Penetrating aortic ulcer with at least one of the following:\n\n    1. Symptomatic\n    2. Ulcer demonstrates expansion\n13. Intramural hematoma with at least one of the following:\n\n    1. Symptomatic (persistent pain)\n    2. Transverse or longitudinal expansion on serial imaging\n14. In the event of a lesion in the ascending aortic, the proximal\u002Fascending native or previously implanted surgical graft the landing zone must be appropriate\n15. Femoral \u002F iliac artery diameter as documented by CTA or MRA that allows endovascular access to the diseased site with a 20 Fr. delivery catheter.\n16. Access vessels morphology suitable for endovascular repair in terms of tortuosity, calcification and angulation, documented by CTA\u002FMRA.\n17. Brachial\u002FAxial Artery diameter that allows endovascular access suitable for 7 Fr.\n18. Subject is considered an appropriate candidate for an elective surgery.\n19. Subject is considered to be at high risk for open repair, as determined by the investigator.\n20. Access vessels, iliac\u002Ffemoral \\& brachial\u002Faxillary compatible with vascular access techniques (femoral cutdown or percutaneous), devices, and \u002For accessories.\n21. Subject is willing and able to comply with procedures specified in the protocol and is able to return for follow-up visits as specified by the protocol.\n\nExclusion Criteria:\n\n1. Acute dissection\n2. Lesions that can be safely treated with TEVAR landing in zone 2 (with or w\u002Fo LSA vascularization)\n3. Required emergent treatment, e.g., trauma, rupture\n4. Acute vascular injury of the aorta due to trauma\n5. Aortic rupture or unstable aneurysm\n6. Received a previous stent or stent graft in the treated area (including planned landing area)\n7. Required surgical or endovascular treatment of an infra-renal aneurysm at time of implantation\n8. Planned major surgical or interventional procedure at time of screening, to be performed after the NEXUS™ implantation.\n9. Any major surgical or interventional procedure 6 weeks before the NEXUS™ implantation, exclusive of planned procedures that are needed for the safe and effective placement of the stent graft (e.g. supra-aortic bypass).\n10. Subject has had a myocardial infarction (MI) or cerebral vascular accident (CVA) within 90 days prior to the planned implantation\n11. Subjects with severe aortic valvular insufficiency as determined by echocardiography\n12. Mechanical valve that preclude safe delivery of NEXUS™\n13. Known Connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndromes)\n14. Subject has an active systemic infection at the time of the procedure documented by pain, fever, drainage, positive culture\n15. Pregnant\n16. Life expectancy of less than 2 years\n17. Unsuitable vascular anatomy\n18. Subject who have a previously implanted surgical wrap of the ascending aorta\n19. Any medical condition that, according to the investigator's decision, might expose the subject to increased risk by the investigational device or procedure.\n20. An aneurysm that is mycotic, inflammatory or suspected to be infected.\n21. Subject with hostile groins\u002Faxilla (scarring, obesity, or previous failed puncture) unless conduit are used.\n22. Subjects with severe atherosclerosis, severe calcification or extensive intraluminal thrombus of the aorta or in the brachiocephalic trunk\n23. Subject is suffering from unstable angina or NYHA classification III and IV.\n24. Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment.\n25. Subject with a contraindication to undergo angiography\n26. Subject with known sensitivities or allergies to the device materials (including Nitinol \\[NiTi\\], polyester fabric \\[PET\\], tantalum \\[TA\\])\n27. Clinical conditions that severely inhibit x-ray visualization of the Aorta.\n28. Subject has history of bleeding diathesis or coagulopathy that may limit the use of dual antiplatelet or anticoagulant therapy by the decision of the investigator\n29. Acute renal failure; chronic renal failure (excluding dialysis); Creatinine \\> 2.00 mg\u002Fdl\n30. Any other medical, social, or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, or the procedures and evaluations pre- and post- treatment.\n31. Active participation in another clinical study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints in this study, or subject is planning to participate in such study prior to the completion of this study.",{"count":440,"type":22},110,[55],"Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.",[28,63,444,378],"Intramural Hematoma","2025-10-16",{"date":447,"type":36},"2025-10-20",{"date":449,"type":36},"2020-10-20",{"date":451,"type":22},"2029-10",{"name":453,"class":128},"Endospan Ltd.",32,{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":44},"100419891","b-safer-branched-stented-anastomosis-frozen-elephant-trunk-repair-100419891","NCT04747626","B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair","B-SAFER","Inclusion Criteria:\n\n1. At least 18 years of age\n2. Subject is willing and able to give written informed consent to participate in the study or the subject's legally authorized representative has given written informed consent for the subject to participate in the study.\n3. Expected life expectancy of greater than two years after repair\n4. Subject has aortic pathology and requires repair or replacement of multiple damaged or diseased segments of the thoracic aorta (at least one of the following condition): Thoracic aortic aneurysm considered at increased risk for rupture or complications, Acute aortic dissection requiring urgent repair, Congenital aortic disease requiring repair\n\nExclusion Criteria:\n\n1. Subject is unfit for open surgical repair involving circulatory arrest\n2. Subject is comatose or suffering from irreversible severe brain malperfusion\n3. Subject has known sensitivity to components of the devices\n4. Subject has an active systemic infection that, in the opinion of the investigator, would compromise the outcome of the surgical procedure\n5. Subject is enrolled in another active study and has received an investigational product (device, pharmaceutical or biologic) within 6 months prior to the date of the implant or has not reached the primary endpoint of the study\n6. Subject has an uncorrectable bleeding anomaly\n7. Subject has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post- procedure\n8. Subject is pregnant",{"count":463,"type":22},590,[55],"A prospective, single-center, non-blind, non-randomized safety and feasibility study of the hybrid repair of thoracic aortic pathologies requiring repair of the aortic arch proximal to the origin of innominate artery.",[467,28,468],"Thoracic Aortic Aneurysm","Congenital Aortic Anomaly","2025-10-07",{"date":471,"type":36},"2025-10-09",{"date":473,"type":36},"2021-03-25",{"date":475,"type":22},"2030-12-31",{"name":477,"class":43},"Eric Roselli, M. D.",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":416,"enrollmentInfo":486,"targetDuration":4,"studyType":23,"phases":488,"briefSummary":489,"conditions":490,"keywords":491,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":44},"100519493","study-comparing-hemiarch-replacement-and-hemiarch-plus-stent-implantation-in-acute-aortic-dissection-100519493","NCT06044259","Study Comparing Hemiarch Replacement and Hemiarch Plus Stent Implantation in Acute Aortic Dissection","Randomized Trial on Acutely Dissected Aorta Repair With Hemiarch Replacement With or Without Stent Implantation (RADAR Trial)","RADAR","Inclusion Criteria:\n\n1. Patient´s age is between 18 and 80 years.\n2. Patient is willing and able to give informed consent.\n3. Patient has acute DeBakey Type I and requires repair or replacement of damaged or diseased vessels of the ascending aorta.\n4. Patient not in coma\u002Firreversible end organ failure\u002Fcardiac massage for resuscitation, at the time of consent.\n\nExclusion Criteria:\n\n1. Patient has aortic arch diameter of more than 4.5 cm\n2. Patient has known connective tissue disease or genetically linked aortopathy\n3. Patient has entry tear more than 2 cm over aortic arch\n4. Patient with DeBakey Type II aortic dissection\n5. Patient has co-morbidity (i.e. active malignancy (progressive, stable or partial remission)) causing expected survival to be less than 2 years.\n6. Patient has any other medical, social, or psychological problems, that in the opinion of the investigator, preclude the patient from participating in this study.",{"count":487,"type":22},72,[55],"Acute DeBakey type I aortic dissection (ATAD) is one of the most lethal surgical emergencies. The conventional operative strategy is hemiarch replacement under cardiopulmonary bypass support to replace the diseased segment of the ascending aorta. However, in patients with dissection involving the whole aortic arch and descending thoracic aorta, the presence of the persistently perfused false lumen can lead to late aneurysm formation and require a second-stage operation, and this reduces long-term survival. In the surgical literature, there is growing evidence that the presence of Distal Anastomosis New Entry (DANE), which is a new intimal defect related to the trauma created by surgical sutures, is associated with persistent perfusion of the false lumen, aortic size growth, and the need of re-operation. The Ascyrus Medical Dissection Stent (AMDS; Artivion, Atlanta, Georgia, USA) is a hybrid prosthesis with a proximal sewing collar and distal nitinol self-expanding un-covered stent system designed to reduce the occurrence of DANE and hopefully depressurize the false lumen and lead to remodeling of the aortic wall.\n\nThe investigators plan to prospectively recruit consecutive patients with acute ascending thoracic aortic dissection patients (Excluding DeBakey II) and randomized them, after informed consent, into either the conventional hemiarch replacement group (Hemiarch-C) or the hemiarch replacement plus AMDS implantation group (Hemiarch-AMDS). The participating team will collect pre-operative, intra-operative and post-operative clinical and radiological parameters for two groups of patients. Written informed consent, specifically allowing the use of clinical records for this randomized study, will be obtained from every patient prior to data collection. Complete DICOM image files of the CT scans will be evaluated by two independent fully qualified Radiologists. Our primary outcome is the radiological detection of DANE in Hemiarch-C and Hemiarch-AMDS groups within the 12-month follow-up period.\n\nThis study will be the world's first randomized control trial in ATAD to compare the prevalence of DANE in Hemiarch-C and Hemiarch-AMDS. It could be a guideline-changing study for the treatment of ATAD and its impact on the immediate survival, second-stage treatment, and long-term survival of patients suffering from ATAD.",[28],[492,493],"Hemiarch replacement","AMDS implantation","2025-09-24",{"date":496,"type":36},"2025-09-29",{"date":498,"type":36},"2023-10-01",{"date":500,"type":22},"2027-09-30",{"name":502,"class":43},"Chinese University of Hong Kong",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":511,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":525},"100353726","hemiarch-vs-extended-arch-in-type-1-aortic-dissection-100353726","NCT03885635","Hemiarch vs Extended Arch in Type 1 Aortic Dissection","Hemiarch vs Extended Arch in Aortic Dissection - a SystemaTic Analysis by Randomized Trial (HEADSTART)","HEADSTART","Inclusion Criteria\n\n1. Emergent surgical repair of Acute DeBakey Type 1 aortic dissection\n2. Age \\>18 years and \\\u003C70 years\n3. Operating surgeon believes that both surgeries could be safe and effective\n\nExclusion Criteria\n\n1. Hemodynamic instability\u002Fshock defined as systolic BP \\\u003C 90 mm Hg\n2. Previous cardiac surgery with sternotomy or thoracic endograft placement\n3. Aortic arch diameter \\> 6cm in which a concomitant arch replacement is judged necessary\n4. Procedures deemed to be \"salvage operations\" where the patient is unlikely to survive hospital discharge.\n5. GCS \\\u003C 8 for more than 6 hours\n6. History of cirrhosis.\n7. History of chronic renal failure (baseline eGFR \\\u003C 50)\n8. Metastatic malignancy\n9. Pregnancy","70 Years",{"count":513,"type":22},50,[55],"HEADSTART is a prospective, open-label, non-blinded, multicenter, randomized controlled trial that compares a composite of mortality and re-intervention in patients undergoing hemiarch and extended arch repair for acute DeBakey type 1 aortic dissection. Eligible patients will be randomized to one or the other surgical strategy and clinical and imaging outcome data will be collected over a 3 year follow up period.",[28],"2025-09-17",{"date":123,"type":36},{"date":520,"type":36},"2024-07-30",{"date":522,"type":22},"2027-03-31",{"name":524,"class":43},"Ottawa Heart Institute Research Corporation",4,{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":546,"locationsCount":548},"100455824","scandinavian-trial-of-uncomplicated-aortic-dissection-therapy-100455824","NCT05215587","Scandinavian Trial of Uncomplicated Aortic Dissection Therapy","SUNDAY","Inclusion Criteria:\n\nAll subjects, aged 18 or greater at the time of informed consent, admitted or referred to the participating vascular surgery site with an uTBAD of less than four weeks duration.\n\nExclusion Criteria:\n\n* Subjects with no signed informed consent.\n* Subjects presenting with a complicated type B aortic dissection according to the above definition.\n* Subjects previously treated in their descending aorta, either open surgery or TEVAR.\n* Subjects with pre-existing thoracoabdominal aortic aneurysm.\n* Subjects with other aortic pathology with an indication for intervention that requires TEVAR.\n* Subjects with traumatic aortic dissections.\n* Subjects with an established connective tissue disease at the time of randomization, including but not limited to Marfans and Loeys-Dietz syndrome.\n* Subjects with a clinically estimated life expectancy \\\u003C 2 years.\n* Subjects with dementia.\n* Pregnant or nursing subjects.\n* Subjects with current sepsis.\n* Subjects currently participating in other clinical interventional trials.",{"count":534,"type":22},554,[55],"The introduction of thoracic endovascular aortic repair (TEVAR) in 1994 has radically changed the treatment of thoracic aortic pathology, and TEVAR is now the recommended therapy for \"complicated\" TBADs and other thoracic aorta diseases. To date, the use of TEVAR in the treatment of \"uncomplicated\" dissections (uTBAD) is uncertain, although it is presumed that a prophylactic procedure can prevent later complex surgery and early death. Several analyses have found that TEVAR confers improved aortic remodeling and possibly survival, although these were underpowered for this specific outcome. In addition, there are several reports regarding the uncertain benefit or harm of this intervention in the vascular surgery community. Put another way, there is equipoise, and the need for robust evidence in the form of a randomized clinical trial has been clearly iterated by the European Society of Vascular Surgery.\n\nThis randomized, open-label, two-armed controlled study directly addresses this question of whether TEVAR alters 5-year survival among patients with an uTBAD. Patients will be randomized to either standard medical therapy (SMT) alone or TEVAR in addition to SMT. The primary outcome is 5-year survival, while secondary outcomes include aortic-related mortality, neurological events, quality of life, costs, re interventions and readmissions. in addition, subgroup analyses based on the extent of treatment.\n\nSample size calculations based on previous reports indicate the need to include approximately 554 patients. Patients will be recruited from multiple centres in Scandinavia. Based on the population (24 million) and incidence of uTBAD (approximately 480 per year), and depending on the total number of participating centres, a conservative estimate of two to three years is required for enrolment.",[28],[539],"Aortic; dissection; TEVAR; endovascular; vascular","2025-08-08",{"date":542,"type":36},"2025-08-11",{"date":544,"type":36},"2023-05-24",{"date":475,"type":22},{"name":547,"class":43},"University of Aarhus",28,{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":416,"enrollmentInfo":556,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":44},"100586451","study-on-the-aortic-arch-single-branch-stent-graft-system-100586451","NCT06915545","Study on the Aortic Arch Single Branch Stent Graft System","Study on the Safety and Efficacy of the Aortic Arch Single Branch Covered Stent System for Aortic Dissection Involving the Aortic Arch","Inclusion Criteria:\n\n* Age between 18 and 80 years, gender unrestricted.\n* Patients are diagnosed with Stanford Type B aortic dissection and need revascularization of the left subclavian artery.\n* Anatomical criteria:\n\n  * The diameter range of the proximal aortic landing zone is 20-42 mm.\n  * The length of the proximal aortic landing zone (the distance from the posterior edge of the left common carotid artery orifice to the first intimal tear) is ≥15 mm.\n  * The distance between the left common carotid artery and the left subclavian artery is ≥5 mm.\n  * The length of the left subclavian artery landing zone is ≥25 mm, and the diameter range of the landing zone is 5-15 mm.\n  * Suitable access to the femoral artery, iliac artery, and upper limb artery.\n* Patients understand the purpose of the study, volunteer to participate, and are willing to complete follow - up visits as required by the protocol.\n\nExclusion Criteria:\n\n* Previously undergone endovascular interventional treatment involving the aortic arch, or having a history of aortic surgical repair surgery, which affects the implantation and evaluation of the single branched covered stent system of the aortic arch.\n* Patients with severe stenosis, calcification, or mural thrombus in the stent anchoring area pose challenges. Such conditions may easily prevent covered stents from adhering to the vessel wall or affect stent patency.\n* Infectious aortic diseases, giant cell arteritis, Marfan syndrome (or other hereditary connective tissue diseases).\n* Patients with systemic or local infections that may increase the risk of infection of the endovascular graft.\n* Patients who have received abdominal aortic surgical or endovascular interventional surgery within the past 3 months.\n* Patients who have had a stroke attack (excluding transient ischemic attack, TIA) or myocardial infarction within the past 3 months.\n* Patients known to be allergic to contrast agents, stent materials, and delivery device materials (referring to nitinol, Dacron, PTFE, nylon polymer materials).\n* Patients known to have contraindications to anticoagulant and antiplatelet drugs.\n* Patients intolerant to general anesthesia.\n* Patients with severe abnormalities in liver, kidney, and cardiac function before the operation \\[Subjects with a serum creatinine level exceeding 150 μmol\u002FL; Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding 5 times the upper limit of the normal value; Subjects with serum total bilirubin (STB) exceeding 2 times the upper limit of the normal value; Subjects with a left ventricular ejection fraction lower than 50% as indicated by echocardiography.\\].\n* Patients whose expected lifespan is shorter than 1 year.\n* Female patients who are planning to conceive, are currently pregnant, or are breastfeeding.\n* Patients whom, in the researcher's judgment, are not appropriate candidates for endovascular treatment.\n* Patients who have been involved in other clinical studies and have not withdrawn from or exited the respective study groups within the three months preceding the screening period of this present study.",{"count":557,"type":22},135,[55],"The objective of the study is to evaluate the Safety and Efficacy of Aortic Arch Single Branch Covered Stent System for Aortic Dissection Involving the Aortic Arch",[28],"2025-06-10",{"date":563,"type":36},"2025-06-11",{"date":565,"type":36},"2025-04-30",{"date":567,"type":22},"2031-06-30",{"name":569,"class":128},"Lifetech Scientific (Shenzhen) Co., Ltd.",{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":583,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":594},"100224613","feasibility-of-endovascular-repair-of-ascending-aortic-pathologies-100224613","NCT02201589","Feasibility of Endovascular Repair Of Ascending Aortic Pathologies","Proposed Single Center Investigational Device Exemption: Feasibility of Endovascular Repair Of Ascending Aortic Pathologies","Inclusion Criteria:\n\n* Patient must have a Type A thoracic aortic dissection, retrograde Type A thoracic aortic dissection, intramural hematoma, penetrating ulcer or pseudoaneurysm of the ascending thoracic aorta affecting the area between the Sinus of Valsalva and the innominate artery orifice (with no involvement of the aortic valve) and be considered candidates for endovascular repair;\n* Patient must also have at least one cm proximal and distal landing zones in the ascending aorta between 28-44 mm in diameter;\n* The patient must be deemed high-risk surgical candidate according to the following established criteria: ASA (American Society of Anesthesiologists) class IV.\n\nExclusion Criteria:\n\n* Pregnant or pediatric patients (younger than 21 years of age);\n* Patients who have a condition that threatens to infect the stent graft\u002Faortic valve prosthesis;\n* Patients with allergies to the stent graft material;\n* Patients or their legally authorized representatives who do not sign the informed consent;\n* Patients with expected survival less than one year.",{"count":303,"type":22},[55],"The purpose of this study is to investigate the outcome of patients with pathologies of the ascending thoracic aorta (diseases in the great blood vessel or artery that leads away from the heart) including type A aortic dissection, retrograde type A aortic dissection, intramural hematoma, penetrating ulcer or pseudoaneurysm who are suitable for endovascular (within the vessel) repair with the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft. Type A aortic dissection is a condition where blood passes through the inner lining or between the layers of the blood vessel from a tear in the aortic wall (dissection) in the ascending aorta; a retrograde Type A aortic dissection is a condition where the dissection or tear in the ascending aorta starts from the descending aorta; an intramural hematoma is a collection of clotted blood within the aortic wall; a penetrating ulcer has a plaque or clot within the wall and a pseudoaneurysm is a false aneurysm . If left untreated in any of these conditions, the aorta can enlarge and rupture causing injury or death. The plan for these patients is to repair the ascending thoracic aorta using the Medtronic Valiant PS-IDE Stent Graft with the Captivia Delivery System. The Valiant Captivia has been evaluated worldwide and used extensively in patients with type B (descending) thoracic aortic dissection. Since the dissections in the ascending aortas mirror that of the descending aorta, it is expected that this stent graft will deliver similar performance and endurance in patients with type A aortic dissection. The investigators expect to reroute the blood to the true lumen (the inner space within the blood vessel) by covering the proximal (nearest to the heart) tear with the stent graft. The stent graft is a stent frame made from Nitinol wire and covered with an expandable material made of a polyester material. This new study will determine how well the device works to treat dissections, intramural hematomas, penetrating ulcers and pseudoaneurysms in the ascending thoracic aorta.",[28,444,581,582],"Penetrating Ulcer","Pseudoaneurysm",[584],"Lesions in the ascending thoracic aorta","2025-05-02",{"date":587,"type":36},"2025-05-06",{"date":589,"type":36},"2013-11",{"date":591,"type":22},"2033-12",{"name":593,"class":43},"Rodney A. White, MD",3,{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":416,"enrollmentInfo":603,"targetDuration":4,"studyType":23,"phases":605,"briefSummary":606,"conditions":607,"keywords":609,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":4},"100588777","guoamps-distal-entry-tear-repair-with-weflow-endopatch-system-gallant-study-100588777","NCT06945809","Guo&Amp;'s Distal Entry Tear Repair With WeFlow-EndoPatch System (Gallant Study)","Guo&Amp;'s Distal Entry Tear Repair: a Multicenter, Prospective, Superiority, Randomized Controlled Trial of the Novel WeFlow-EndoPatch Aortic Endovascular Patch System","Gallant","Inclusion Criteria:\n\n* Patients aged 18 to 80 years old, no gender limitation;\n* The patient was diagnosed with chronic aortic dissection after the repair of the main artery dissection, with distal tears required seal;\n* The maximum diameter of the descending thoracic aorta is 3.5-5cm；\n* The number of thoracic descending aorta tears is ≤2, and the maximum diameter of the tears is 2-30 mm；\n* With appropriate artery approaches, endovascular treatment can be performed；\n* Those who can understand the purpose of the trial, voluntarily participate in the study, sign the informed consent form by themselves or their legal representative, and are willing to complete the follow-up according to the protocol requirements.\n\nExclusion Criteria:\n\n* Rupture or threatened rupture of aortic dissection;\n* Proximal type I internal leakage after aortic repair;\n* New distal SINE;\n* Abdominal aortic dissection aneurysm diameter ≥5 cm;\n* The edge of the tear from the opening of celiac trunk is\\\u003C4 mm;\n* The same operation requires intervention in other vascular diseases (such as coronary artery, renal artery, superior mesenteric artery, etc.);\n* Acute systemic infection;\n* History of myocardial infarction, TIA or cerebral infarction within the past 3 months;\n* Cardiac function Grade IV (NYHA rating) or LVEF \\< 30%;\n* Hematological abnormalities: leukopenia (WBC \\< 3×10\\^9\u002FL), anemia (Hb \\< 90 g\u002FL); Coagulation dysfunction, thrombocytopenia (PLT count \\< 50×10\\^9\u002FL);\n* Renal insufficiency: serum creatinine \\> 150 umol\u002FL (or 3.0 mg\u002FdL) and\u002For advanced kidney disease requiring renal dialysis, as determined by the investigator after thorough analysis;\n* Severe liver insufficiency: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds the normal upper limit by 5 times; Serum total bilirubin (STB) exceeded the normal upper limit by 2 times;\n* Allergic to contrast agents, anesthetics, patchs, and delivery materials;\n* Pregnant or breastfeeding;\n* Participated in clinical trials of other drugs or devices during the same period;\n* Life expectancy is less than 12 months (such as advanced malignant tumors); Investigator judged that not suitable for interventional treatment.",{"count":604,"type":22},204,[55],"A Multicenter, Randomized Controlled Study About the Safety and Efficacy of WeFlow-EndoPatch Aortic Endovascular Patch System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for Chronic Aortic Dissection . (GALLANT Study)",[28,608],"Distal Entry Tear",[28,610,611],"Distal tear","descending aorta","2025-04-27",{"date":565,"type":36},{"date":615,"type":22},"2025-10",{"date":617,"type":22},"2032-10",{"name":619,"class":128},"Hangzhou Endonom Medtech Co., Ltd.",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":627,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":629,"conditions":630,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":44},"100581767","pocus-screening-for-taa-in-hypertensive-patients-in-the-ed-100581767","NCT06854588","POCUS Screening for TAA in Hypertensive Patients in the ED","Point-of-care Ultrasound Screening of Thoracic Aortic Aneurysm in Hypertensive Patients in the Emergency Department","Inclusion Criteria:\n\n* Adult patients aged ≥ 18 years attending the ED during the study period\n* Known history of hypertension or newly diagnosed hypertension in the ED\n\nExclusion Criteria:\n\n* Known history of aortic aneurysm or dissection\n* Previous thoracic aortic interventions or endovascular stenting\n* Patients in cardiopulmonary resuscitation\n* Traumatic patients\n* Patients refuse to participate the study",{"count":628,"type":22},1483,"The investigators are going to recruit hypertensive patients in the emergency department of Prince of Wales Hospital. Point-of-care ultrasound of the aorta and measurements of the aortic diameter will be obtained. Other relevant clinical data will also be obtained for analysis. The primary outcome is the number of patients with a maximum aortic diameter of ≥ 4.5 cm and\u002For ≥ 50% localized enlarged diameter relative to the adjacent normal segment as indicated by POCUS.",[96,28],"2025-03-11",{"date":633,"type":36},"2025-03-13",{"date":635,"type":22},"2025-03",{"date":637,"type":22},"2026-02",{"name":502,"class":43},{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":648,"conditions":649,"keywords":650,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":44},"100582382","nordic-consortium-for-acute-type-a-aortic-dissection-2-100582382","NCT06862583","Nordic Consortium for Acute Type a Aortic Dissection-2","Nordic Multicenter Study of Risk Factors, Surgical Treatment and Outcomes in Acute Type a Aortic Dissection","NORCAAD-2","Inclusion Criteria:\n\n* Acute (within 14 days of onset) type A aortic dissection or similar acute aortic syndrome\n\nExclusion Criteria:\n\n* Age \\\u003C18 years at onset",{"count":290,"type":22},"The Nordic Consortium for Acute Type A Aortic Dissection-2 (NORCAAD-2) is a multicenter research collaboration involving up to 19 units in the Nordic countries and one in The Netherlands. All patients referred for this condition is included, to outline detailed preoperative characteristics and risk factors as well as, for those operated, data on the operative procedure, the postoperative course including major and minor complications and, as the primary interest, mortality in short- and long-term perspective. The need for further procedures on the aorta will also be studied.\n\nAcute type A Aortic Dissection (ATAAD) is a vascular emergency with very high case-fatality rate. The condition is realtively infrequent, and single units can rarely amass sufficient number of patients during a reasonable time to analyse also unusual variants in background, presentation, and management. Randomized controlled trials are unlikely, and large multicenter databases are the best source of knowledge for the foreseeable future. Other such databases exist, but NORCAAD-2 is more focused (only ATAAD) and more detailed than many counterparts, with the ability to extract unique information.\n\nNORCAAD-2 is the extension and expansion of the original NORCAAD project. NORCAAD-2 includes more centers, more patients, more data and utilizes a novel on-line common database designed for the purpose.\n\nThe ultimate goal is to identify novel risk markers to help inform decisions on pre-emptive surgery (before ATAAD occurs); to outline superior perioperative techniques and strategies to optimize outcomes both short- and long-term; and to analyze variables related to major complications, in an effort to further reduce their incidence.",[28],[651,652,653,654,655,656,657],"Open surgery","Risk factors","Outcomes","Mortality","Circulatory arrest","cerebral protection","bicuspid aortic valve","2025-03-03",{"date":660,"type":36},"2025-03-06",{"date":662,"type":36},"2019-06-03",{"date":664,"type":22},"2030-06",{"name":666,"class":43},"Karolinska Institutet"]